The process by which vaccines for COVID-19 have emerged over the past year is a powerful illustration of how supply chains are evolving in the 21st century. Although many of the economic processes are not entirely new, the creation and production of the vaccines demonstrate how intellectual property and physical production can be brought together. They may also demonstrate the problems.
This paper compares and contrasts the supply chains of two of the largest players to have successfully brought their vaccines to market, Pfizer and AstraZeneca.
Enter your details below to download the whitepaper:
